MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-03-2026
Rigel Pharmaceuticals Income Statement 2011-2026 | RIGL
Annual Income Statement Rigel Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
598 M | 393 M | 25.9 M | 25.2 M | 436 M | 614 M | 392 M | 348 M | 504 M | 196 M | 243 M | 181 M | 275 M | 479 M | 615 M |
Shares |
18 M | 17.6 M | 17.4 M | 17 M | 170 M | 169 M | 167 M | 161 M | 126 M | 94.4 M | 88.4 M | 87.7 M | 87.3 M | 75 M | 63.3 M |
Historical Prices |
33.2 | 22.4 | 1.49 | 1.48 | 2.56 | 3.64 | 2.26 | 2.16 | 4 | 2.08 | 2.75 | 2.07 | 3.03 | 6.56 | 9.77 |
Net Income |
367 M | 17.5 M | -25.1 M | -58.6 M | -17.9 M | -29.7 M | -66.9 M | -70.5 M | -78 M | -69.2 M | -51.5 M | -90.9 M | -89 M | -98.8 M | -86 M |
Revenue |
294 M | 179 M | 117 M | 120 M | 149 M | 109 M | 59.3 M | 44.5 M | 4.48 M | 20.4 M | 28.9 M | 8.25 M | 7.15 M | 2.25 M | 4.75 M |
Cost of Revenue |
19.6 M | 18.6 M | 7.11 M | 1.75 M | 1.08 M | 895 K | 906 K | 287 K | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | 58.4 M | 44.2 M | - | - | 28.9 M | 8.25 M | 7.15 M | 2.25 M | 4.75 M |
Operating Income |
125 M | 24.2 M | -20.5 M | -55.6 M | -12.5 M | -29 M | -69.1 M | -72.7 M | -79.6 M | -69.7 M | -51.7 M | -91.2 M | -89.5 M | -99.4 M | -86.4 M |
Interest Expense |
- | - | - | 3.71 M | 4.86 M | 1.35 M | 335 K | - | - | - | - | - | - | - | 25 K |
EBITDA |
128 M | 26.4 M | -19.3 M | -54.6 M | -11.3 M | -28.3 M | -68.4 M | -72.1 M | -79.2 M | -63 M | -50.3 M | -88.9 M | -85.2 M | -96.9 M | -84.4 M |
Operating Expenses |
- | - | - | - | - | - | 127 M | 117 M | 84.1 M | 84.4 M | 80.6 M | 99.5 M | 94.9 M | 102 M | 91.1 M |
General and Administrative Expenses |
116 M | 113 M | 106 M | 112 M | 91.9 M | 76.6 M | 74.6 M | 70 M | 37.8 M | 20.9 M | 17.8 M | 31.8 M | 19.6 M | 22.8 M | 21.8 M |
All numbers in USD currency
Quarterly Income Statement Rigel Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
18 M | 17.9 M | 17.8 M | 17.6 M | 17.5 M | 17.5 M | 17.4 M | 17.4 M | 174 M | - | 173 M | 172 M | 172 M | 172 M | 171 M | 170 M | 170 M | 169 M | 169 M | 169 M | 168 M | 168 M | 168 M | 167 M | 167 M | 167 M | 166 M | 162 M | 147 M | 144 M | 125 M | 122 M | 114 M | 99 M | 95.5 M | 92.5 M | 90.6 M | 89 M | 88.5 M | 88.1 M | 88 M | 87.8 M | 87.8 M | 87.5 M | 87.5 M | 87.4 M | 87.4 M | 87.1 M | 87.1 M | 85.3 M | 71.6 M | 71.5 M | 71.4 M | 71.2 M | 71.2 M | 58.3 M | 52.3 M |
Net Income |
27.9 M | 59.6 M | 11.4 M | 12.4 M | -1.03 M | -8.25 M | -5.69 M | -6.6 M | -13.5 M | - | -19 M | -13.5 M | -27.4 M | - | -21 M | -13.8 M | 39.5 M | -19.2 M | -14.2 M | 3.67 M | 21.2 M | -17.2 M | -49.7 M | -38.2 M | -17.6 M | 3.23 M | -73.7 M | -49.9 M | -24.4 M | -25.9 M | -52.1 M | -34.5 M | -15.3 M | -15.6 M | -53.6 M | -31 M | -17.5 M | -12.7 M | -6.67 M | -13.9 M | -18.2 M | -22.3 M | -20.9 M | -25.4 M | -22.3 M | -16.9 M | -23.8 M | -22.8 M | -25.6 M | -25.5 M | -25.5 M | -24.7 M | -23.2 M | -25.8 M | -17.9 M | -21.5 M | -20.8 M |
Revenue |
69.5 M | 102 M | 53.3 M | 55.3 M | 36.8 M | 29.5 M | 28.1 M | 26.9 M | 26.1 M | - | 22.4 M | 29.8 M | 16.7 M | - | 21.5 M | 26.3 M | 81 M | 18.4 M | 18.4 M | 16 M | 55.8 M | 15.4 M | 20.9 M | 10.4 M | 12.6 M | 37.9 M | 4.86 M | 1.79 M | - | - | 900 K | 3.58 M | 3.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
4.75 M | 4.5 M | 4.41 M | 8.03 M | 2.81 M | 2.02 M | 1.27 M | 1.08 M | 977 K | - | 250 K | 1.04 M | 121 K | - | 151 K | 129 K | 316 K | - | 140 K | 279 K | 155 K | - | 310 K | 311 K | 107 K | - | 69 K | 30 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.4 M | 16.1 M | 14.7 M | 12.5 M | 13.7 M | 11.4 M | 9.86 M | 7.95 M | 7.11 M | 4.8 M | 1.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
28.4 M | 61.1 M | 12.8 M | 14.1 M | 447 K | -6.97 M | -4.46 M | -5.27 M | -12.7 M | - | -18.4 M | -13 M | -26.3 M | - | -19.8 M | -13 M | 41.8 M | - | -13.8 M | -17.4 M | 21 M | - | -12 M | -21.3 M | -18.4 M | - | -24.4 M | -26.1 M | -24.7 M | - | -17.9 M | -19.3 M | -16.2 M | - | -22.7 M | -13.6 M | -17.6 M | - | -6.78 M | -14 M | -18.2 M | - | -21 M | -25.5 M | -22.4 M | - | -23.9 M | -22.9 M | -25.7 M | - | -25.6 M | -24.9 M | -23.3 M | - | -18 M | -21.6 M | -20.9 M |
Interest Expense |
1.89 M | 1.87 M | 1.85 M | 2.06 M | 2.03 M | 1.87 M | 1.9 M | 1.86 M | 1.2 M | - | 826 K | 569 K | 1.2 M | - | 1.32 M | 1.76 M | 485 K | - | 429 K | 353 K | 142 K | - | 8 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4 K | 7 K | 11 K |
EBITDA |
29 M | 61.7 M | 13.4 M | 14.7 M | 1.05 M | -6.57 M | -4.16 M | -4.97 M | -12.4 M | - | -17.7 M | -13 M | -26 M | - | -19 M | -13 M | 42 M | - | -13.3 M | -17.1 M | 21.2 M | - | -11.5 M | -21 M | -18.2 M | - | -23.9 M | -25.8 M | -24.6 M | - | -17.5 M | -19.1 M | -16.1 M | - | -21.9 M | -13.1 M | -17.2 M | - | -5.68 M | -13.2 M | -17.8 M | - | -19.2 M | -24.2 M | -21.7 M | - | -22 M | -21.6 M | -25 M | - | -23.8 M | -23.7 M | -22.8 M | - | -16.6 M | -20.6 M | -20.4 M |
General and Administrative Expenses |
28.9 M | 29.3 M | 27.7 M | 27 M | 28 M | 28.4 M | 24.9 M | 26.3 M | 27.7 M | - | 25.9 M | 27 M | 27.4 M | - | 22.9 M | 22.4 M | 22.1 M | - | 17.4 M | 18.9 M | 18.4 M | - | 18.1 M | 18.2 M | 19.9 M | - | 18.1 M | 17.1 M | 13.5 M | - | 7.95 M | 7.82 M | 7.41 M | - | 4.56 M | 4.77 M | 4.42 M | - | 4.28 M | 4.1 M | 4.72 M | - | 4.89 M | 5.39 M | 5.52 M | - | 4.68 M | 4.89 M | 5.4 M | - | 5.38 M | 5.46 M | 6.16 M | - | 5.08 M | 4.84 M | 5.75 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Rigel Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Germany
USA
Irlanda
China
France
Danmark
Britain
Canada
Russia
Israel
Cayman-islands
